Here are the key details to know:
1. Revenue for the fourth quarter totaled $715,000, compared to $701,000 from the prior year quarter.
2. EyePoint Pharmaceuticals’ revenue for the year ending June 30, 2018 was $3 million compared to $7.5 million from the year prior. The previous year included deferred collaborative research and development revenue of $5.6 million from the termination of a Pfizer collaboration contract.
3. Net loss for the year was $53.2 million, or $1.15 per share. The net loss for the year prior was $18.5 million, or $0.52 per share.
4. Company milestones for the fourth quarter include the appointment of Göran Ando, MD, as the next chairman of the board and securing a transitional pass-through reimbursement from CMS for DEXYCU, a drug used to treat cataract surgery inflammation.
5. EyePoint Pharmaceuticals is also transitioning from a clinical-stage company into a commercial one ahead of future ophthalmic product launches.
More articles on supply chain:
EyePoint Pharmaceuticals appoints new chairman of the board: 3 key details
4 ways to automate an ASC supply chain
ASC supply chain tip of the day: Copy what works at hospitals
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.